Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Disparities in advanced ovarian cancer treatment exist. Non-Hispanic Black patients and older individuals received fewer poly ADP-ribose polymerase inhibitors (PARPi) and bevacizumab therapies, indicating a widening gap in targeted cancer care.
Area Of Science
- Oncology
- Health Services Research
- Pharmacogenomics
Background
- Advanced ovarian cancer treatment has evolved with targeted therapies like PARPi and bevacizumab.
- Understanding disparities in the uptake of these crucial treatments is essential for equitable patient care.
Purpose Of The Study
- To investigate sociodemographic and racial disparities in the utilization of poly ADP-ribose polymerase inhibitors (PARPi) and bevacizumab among insured patients with advanced ovarian cancer.
Main Methods
- A retrospective analysis of the SEER-Medicare database (2010-2019) identified patients with advanced, high-grade serous ovarian cancer.
- Treatment receipt (PARPi and/or bevacizumab) was the primary outcome, analyzed using chi-squared tests and multivariable logistic regression.
Main Results
- Among 6242 patients, 4.4% received PARPi, 34.3% received bevacizumab, and 6.2% received both.
- Younger patients, those with lower comorbidity, and higher socioeconomic status were more likely to receive targeted therapy.
- Non-Hispanic Black patients (OR 0.77) and older patients (>74 years) were significantly less likely to receive PARPi or bevacizumab.
Conclusions
- Significant sociodemographic and racial disparities persist in the receipt of PARPi and bevacizumab for advanced ovarian cancer patients.
- The increasing use of these targeted therapies may exacerbate existing disparities in cancer treatment access.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...